OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research

Rhea-AI Summary

OpenFold, a non-profit AI research consortium, has announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. This consortium focuses on developing free and open-source software tools for biology and drug discovery. The growth in membership reflects the momentum from previous developments, including the release of a protein structure prediction AI model. OpenFold aims to leverage AI to enhance drug discovery and accelerate research, benefiting academics and biotech firms alike.

Positive

• Addition of Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. enhances consortium capabilities.
• Continued momentum with the introduction of advanced AI models for drug discovery.
• OpenFold's mission to make powerful AI tools accessible fosters innovation in pharmaceuticals and biology.

Negative

• None.

 The non-profit consortium is developing publicly accessible advanced drug discovery software tools

DAVIS, Calif.--(BUSINESS WIRE)-- OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd.

OpenFold, a consortium of academic and industry partners founded in February 2022, is a project of the Open Molecular Software Foundation, a non-profit organization advancing molecular sciences by building communities for open source research software development. The four new members join OpenFold’s founders: Mohammed AlQuraishi’s Laboratory, Cyrus Biotechnology, Arzeda, Outpace Bio and Genentech’s Prescient Design.

Bayer of Leverkusen, Germany, is a global enterprise with core competencies in the life science fields of health care and nutrition. Dassault Systèmes SE, of Velizy-Villacoublay, France, develops software to create 3D virtual environments for product design, simulation, and manufacturing. CHARM Therapeutics of London is applying 3D deep-learning technology for drug discovery and development. BaseCamp Ltd of London has created Knowledge Graph, a database of proteins from previously undiscovered organisms found in diverse natural environments, for development of new drugs, diagnostics and agricultural products.

“This growth in membership continues the momentum generated after the formation of the consortium, as well as the introduction of the first Consortium-released protein structure prediction AI model developed in Dr. Mohammed AlQuraishi’s laboratory, both in June of this year,” said Brian Weitzner, Ph.D. Outpace Bio’s Associate Director of Computational and Structural Biology and a co-founder of OpenFold.

“At Bayer, we are driving innovation and transformation. We are excited to be partners with OpenFold, where we can work with leading experts across industries to develop the best methodologies for pharmaceutical and agricultural product design. By computationally simplifying our discovery process, we can increase the speed and quality of product design,” said Dr. Ruth Wagner, VP, Head of Plant Biotechnology Data Science & Analytics at Bayer’s Crop Science division.

“By joining the growing OpenFold community we are excited to strengthen the use of AI in our discovery solution experiences." Reza Sadeghi, Chief Strategy Officer BIOVIA, Dassault Systemes.

OpenFold’s mission is to bring the most powerful software ever created -- AI systems with the ability to engineer the molecules of life -- to everyone. These tools can be used by academics, biotech and pharmaceutical companies, or students learning to create the medicines of tomorrow, to accelerate basic biological research, and bring new cures to market that would be impossible to discover without AI.

About OpenFold

OpenFold is a non-profit artificial intelligence (AI) research consortium of academic and industry partners whose goal is to develop free and open-source software tools for biology and drug discovery, hosted as a project of the Open Molecular Software Foundation. Membership is encouraged among Biotech, Pharma, Synthetic Bio, Software/Tech, and non-profit research organizations. For more information please visit: OpenFold Consortium.

Join OpenFold

Press and membership inquiries should be directed to info@openfold.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005163/en/

OpenFold

info@openfold.io

Source: Open Molecular Software Foundation

FAQ

What is OpenFold?

OpenFold is a non-profit AI research consortium aimed at developing free and open-source software tools for biology and drug discovery.

What companies joined OpenFold recently?

Recently, Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. joined OpenFold.

What is the primary goal of OpenFold?

The primary goal of OpenFold is to leverage AI in advancing drug discovery and biological research.

How does OpenFold benefit the pharmaceutical industry?

OpenFold's tools aim to accelerate drug discovery processes, improving efficiency and outcomes in pharmaceutical research.

When was OpenFold founded?

OpenFold was founded in February 2022.

What is the significance of the new members joining OpenFold?

The new members enhance OpenFold's capabilities and broaden its collaborative efforts in AI and drug discovery.

How can academic and biotech organizations benefit from OpenFold?

They can access powerful AI tools to accelerate basic biological research and drug development.